Australian unlisted biotech company developing antibiotic resistance breakers and antibiofilm agents to reverse resistance to first-line antibiotics. Our lead candidate for chronic respiratory infection mitigation is in Phase 1 clinical trials as an inhaled companion drug to standard of care antibiotics. The technology consists of a class of small molecules, water soluble, orally bioavailable with broad spectrum efficacy in sensitizing resistant bacteria to antimicrobials, rapidly collapsing recalcitrant bacterial biofilm colonies and protecting the host body against endotoxicity/inflammation. Clinical intravenous, oral and topical safety and pharmacokinetics data available.